Status:
UNKNOWN
Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Stable Angina
Percutaneous Coronary Intervention
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Percutaneous coronary intervention (PCI) is associated with up to 30% incidence of myonecrosis, as reflected by elevation of cardiac enzymes in a successful procedure. Apart from side-branch occlusion...
Eligibility Criteria
Inclusion
- Baseline creatine-kinase (CK) and creatine-kinase-myocardial band (CK-MB) had to be within normal limits (a normal CK and CK-MB and elevated troponin allowed inclusion)
Exclusion
- Occlusion resulting in Thrombolysis In Myocardial Infarction (TIMI) grade 0 antegrade flow
- Thrombus-laden lesions
- Significant left main coronary stenosis
- Left ventricular ejection fraction 30%
- Inability to give informed consent
- Bradycardia with heart rate below 50 b.p.m.
- Allergy to adenosine
- The occurrence of myo-cardial infarction within one week
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00751491
Start Date
September 1 2008
End Date
September 1 2009
Last Update
May 6 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Policlinico Umberto I
Rome, Italy, 00161